ReviewMedicina (Kaunas, Lithuania)2019
Suicide in Schizophrenia: An Educational Overview.
Review in Medicina (Kaunas, Lithuania), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 5 syntheses or guidelines pooled it, 206 citations in OpenAlex.
- Metacognitive training for psychosis (MCT): a systematic meta-review of its effectiveness.Translational psychiatry · 2025Pooled it
- Does KarXT (xanomeline-trospium) represent a novel approach to schizophrenia management? A GRADE-assessed systematic review and meta-analysis of randomized controlled clinical trials.BMC psychiatry · 2025Pooled it
- Healthcare professionals' knowledge, confidence and attitudes in relation to psychosis care: A systematic review.The International journal of social psychiatry · 2023Pooled it
- Increased C-reactive protein concentration and suicidal behavior in people with psychiatric disorders: A systematic review and meta-analysis.Acta psychiatrica Scandinavica · 2021Pooled it
- Worldwide prevalence of suicidal ideation and suicide plan among people with schizophrenia: a meta-analysis and systematic review of epidemiological surveys.Translational psychiatry · 2021Pooled it
- Untargeted plasma metabolomics identifies metabolite signatures associated with suicidality status in chronic schizophrenia.European archives of psychiatry and clinical neuroscience · 2026Article
- Higher peripheral blood homocysteine levels are associated with schizophrenia: evidence from a case-control study and a meta-analysis.Molecular psychiatry · 2026Article
- Socioeconomic Disparities in Post-Discharge Suicide Risk Among Individuals With Schizophrenia: A Population-Based Cohort Study in Korea.Journal of Korean medical science · 2026Article
- Preparing an Intervention to Increase Engagement with the 988 Suicide and Crisis Lifeline Resource among Community Mental Health Consumers with Schizophrenia Spectrum Disorders.Community mental health journal · 2026Article
- Direct and Indirect Effects of Body Dysmorphic Concern on Psychotic Symptoms Through Suicidal Ideation in Patients With First-Episode Schizophrenia.Early intervention in psychiatry · 2026Article
- Characterizing artificial intelligence (AI) psychosis in a large academic medical setting: evidence of the new clinical phenomenon and the vulnerability of those in early phases of psychosis.medRxiv : the preprint server for health sciences · 2026Article
- Explainable AI based ensemble model for the identification of Schizophrenia prodromal phase.Scientific reports · 2026Article
- Association of metabolic syndrome with comorbid major depressive disorder in remitted schizophrenia: a cross-sectional study.BMC psychiatry · 2026Article
- Social Isolation and Aging health in Schizophrenia spectrum disorders (SIAS): study protocol for a multinational longitudinal study.BMC psychiatry · 2026Article
- Effectiveness of herbal medicine as an add-on to antipsychotics in patients with schizophrenia spectrum disorders accompanied by depression: A systematic review and meta-analysis.Integrative medicine research · 2026Review
- Distress as a bridge to suicidality in schizophrenia spectrum disorders: a network-based intervention simulation study.Research square · 2026Article
- Investigation of leptin and leptin receptor gene polymorphisms in schizophrenia: further support for an association with attempted suicide.Acta neuropsychiatrica · 2026Article
- MMP9 Genetic Variants in Schizophrenia Spectrum Disorders and Its Relation with Cognitive Dysfunction and Suicide Attempt.Indian journal of psychological medicine · 2026Article
- Digitalized suicide risk assessment in emergency psychiatry services.Frontiers in psychiatry · 2026Article
- Explainable artificial intelligence (XAI) in schizophrenia: enhancing transparency in clinical decision-making.Frontiers in systems biology · 2026Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Suicide is an important public health problem. The most frequent psychiatric illnesses associated with suicide or severe suicide attempt are mood and psychotic disorders. The purpose of this paper is to provide an educational overview of suicidal behavior in individuals with schizophrenia. A lifetime suicide rate in individuals with schizophrenia is approximately 10%. Suicide is the largest contributor to the decreased life expectancy in individuals with schizophrenia. Demographic and psychosocial factors that increase a risk of suicide in individuals with schizophrenia include younger age, being male, being unmarried, living alone, being unemployed, being intelligent, being well-educated, good premorbid adjustment or functioning, having high personal expectations and hopes, having an understanding that life's expectations and hopes are not likely to be met, having had recent (i.e., within past 3 months) life events, having poor work functioning, and having access to lethal means, such as firearms. Throughout the first decade of their disorder, patients with schizophrenia are at substantially elevated suicide risk, although they continue to be at elevated suicide risk during their lives with times of worsening or improvement. Having awareness of symptoms, especially, awareness of delusions, anhedonia, asociality, and blunted affect, having a negative feeling about, or non-adherence with, treatment are associated with greater suicide risk in patients with schizophrenia. Comorbid depression and a history of suicidal behavior are important contributors to suicide risk in patients with schizophrenia. The only reliable protective factor for suicide in patients with schizophrenia is provision of and compliance with comprehensive treatment. Prevention of suicidal behavior in schizophrenia should include recognizing patients at risk, delivering the best possible therapy for psychotic symptoms, and managing comorbid depression and substance misuse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.